Recently, high number of CD163+ TAMs was also correlated with poor prognosis characterized by decreased PFS and complete remission/near-complete remission in MM patients receiving bortezomib-based chemotherapy [74]. This evidence concerns the gene CD163 and Miyoshi myopathy.